Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Stephanie K. Rubel, Matthew Eisenstat, Jessica Wolff, Michael Calevski & Sasha Mital. (2023) Scope of, Motivations for, and Outcomes Associated with Buprenorphine Diversion in the United States: A Scoping Review. Substance Use & Misuse 58:5, pages 685-697.
Read now
Read now
Peter C. Treitler, Michael Enich, Donald Reeves & Stephen Crystal. (2022) Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons. Substance Abuse 43:1, pages 964-971.
Read now
Read now
Katherine McLean & Philip R. Kavanaugh. (2022) “I’m Not a Good Drug Dealer”: Styles of Buprenorphine Diversion in a Multisite Qualitative Study. Substance Use & Misuse 57:3, pages 452-460.
Read now
Read now
Grant Victor, Emily Sightes, Dennis P. Watson, Bradley Ray, Katie Bailey, Lisa Robision, Gina Fears, Rhiannon Edwards & Michelle Salyers. (2021) Designing and implementing an intervention for returning citizens living with substance use disorder: discovering the benefits of peer recovery coach involvement in pilot clinical trial decision-making. Journal of Offender Rehabilitation 60:2, pages 138-158.
Read now
Read now
Noa Krawczyk, Ramin Mojtabai, Elizabeth A. Stuart, Michael I. Fingerhood, Deborah Agus, B. Casey Lyons, Jonathan P. Weiner & Brendan Saloner. (2021) Opioid agonist treatment is highly protective against overdose death among a U.S. statewide population of justice-involved adults. The American Journal of Drug and Alcohol Abuse 47:1, pages 117-126.
Read now
Read now
Bennett Allen, Michelle L. Nolan & Denise Paone. (2019) Underutilization of medications to treat opioid use disorder: What role does stigma play?. Substance Abuse 40:4, pages 459-465.
Read now
Read now
Articles from other publishers (36)
Elizabeth A. Evans, Ekaterina Pivovarova, Rithika Senthilkumar, Rebecca E. Rottapel, Thomas J. Stopka, Claudia Santelices, Warren J. Ferguson & Peter D. Friedmann. (2023) Diversion of medications to treat opioid use disorder: Qualitative findings from formerly incarcerated adults in Massachusetts. International Journal of Drug Policy 122, pages 104252.
Crossref
Crossref
Zoe Friedmann, Hans-Tilmann Kinkel, Claudia Kühner, Andreas Zsolnai, Inge Mick & Annette Binder. (2023) Supervised on-site dosing in injectable opioid agonist treatment-considering the patient perspective. Findings from a cross-sectional interview study in two German cities. Harm Reduction Journal 20:1.
Crossref
Crossref
Kaitlyn Jaffe & Lindsey Richardson. (2023) “I thought it was for guys that did needles”: Medication perceptions and lay expertise among medical research participants. Journal of Substance Use and Addiction Treatment 154, pages 209134.
Crossref
Crossref
Alison Adams, Sarin Blawatt, Scott MacDonald, Rhys Finnick, Julie Lajeunesse, Scott Harrison, David Byres, Martin T. Schechter & Eugenia Oviedo-Joekes. (2023) Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review. International Journal of Drug Policy 117, pages 104058.
Crossref
Crossref
Katie Fitzgerald Jones, Monica O’Reilly Jacob, Joanne Spetz, Laurie Hailer & Matthew Tierney. (2023)
Eliminate the buprenorphine
DEA
X waiver: Justification using a policy analysis approach
. Journal of Nursing Scholarship 55:3, pages 655-664.
Crossref
Crossref
Liam Michaud, Emily van der Meulen & Adrian Guta. (2022) Between Care and Control: Examining Surveillance Practices in Harm Reduction. Contemporary Drug Problems 50:1, pages 3-24.
Crossref
Crossref
Sara Whaley, Sachini Bandara, Karen Taylor & Noa Krawczyk. (2023) Expanding buprenorphine in U.S. jails: One county's response to addressing the fears of diversion. Journal of Substance Use and Addiction Treatment 146, pages 208944.
Crossref
Crossref
David Tyler Coyle, Stephanie Stewart, Cole Bortz, Jane Manalo, Alexis Ritvo & Martin Krsak. (2023) Buprenorphine Prescribing and Dosing Limits: Evidence and Policy Goals. Substance Abuse 44:1-2, pages 17-23.
Crossref
Crossref
Lucinda A. Grande, Dave Cundiff, Mark K. Greenwald, MaryAnne Murray, Tricia E. Wright & Stephen A. Martin. (2023) Evidence on Buprenorphine Dose Limits: A Review. Journal of Addiction Medicine Publish Ahead of Print.
Crossref
Crossref
Kasunka Kankanam Gamage, Serena Tejpar, Umair Majid, Kirsten Dixon, Pamela Sabioni & Abhimanyu Sud. (2023) Bridging the Macro-micro Divide: A Qualitative Meta-synthesis on the Perspectives and Experiences of Health Care Providers on the Extramedical Use and Diversion of Buprenorphine. Journal of Addiction Medicine 17:1, pages e1-e10.
Crossref
Crossref
Jeffrey P. Bratberg & Alyssa Falleni. (2023) Preserving dignity through expanded and sustained access to buprenorphine. Journal of the American Pharmacists Association 63:1, pages 220-223.
Crossref
Crossref
Noa Krawczyk, Sachini Bandara, Sydney Merritt, Hridika Shah, Alexandra Duncan, Brendan McEntee, Maria Schiff, N. Jia Ahmad, Sara Whaley, Amanda Latimore & Brendan Saloner. (2022) Jail-based treatment for opioid use disorder in the era of bail reform: a qualitative study of barriers and facilitators to implementation of a state-wide medication treatment initiative. Addiction Science & Clinical Practice 17:1.
Crossref
Crossref
Noa Krawczyk, Hannah Maniates, Eric Hulsey, Jennifer S. Smith, Ellen DiDomenico, Elizabeth A. Stuart, Brendan Saloner & Sachini Bandara. (2022) Shifting Medication Treatment Practices in the COVID-19 Pandemic: A Statewide Survey of Pennsylvania Opioid Treatment Programs. Journal of Addiction Medicine 16:6, pages 645-652.
Crossref
Crossref
Ashley Buchanan, Tianyu Sun, Jing Wu, Hilary Aroke, Jeffrey Bratberg, Josiah Rich, Stephen Kogut & Joseph Hogan. (2022) Toward evaluation of disseminated effects of medications for opioid use disorder within provider‐based clusters using routinely‐collected health data. Statistics in Medicine 41:18, pages 3449-3465.
Crossref
Crossref
Elizabeth A. Evans, Ekaterina Pivovarova, Thomas J. Stopka, Claudia Santelices, Warren J. Ferguson & Peter D. Friedmann. (2022) Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail. Journal of Substance Abuse Treatment 138, pages 108746.
Crossref
Crossref
Kara E. Rudolph, Matisyahu Shulman, Marc Fishman, Iván Díaz, John Rotrosen & Edward V. Nunes. (2021) Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse. Addiction 117:3, pages 637-645.
Crossref
Crossref
Paxton Bach, Misha Bawa, Cameron Grant, M.J. Milloy & Kanna Hayashi. (2022) Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014–2020. International Journal of Drug Policy 101, pages 103545.
Crossref
Crossref
Julia Dickson-Gomez, Antoinette Spector, Margaret Weeks, Carol Galletly, Madelyn McDonald & Helena Danielle Green Montaque. (2022) “You’re Not Supposed to be on it Forever”: Medications to Treat Opioid Use Disorder (MOUD) Related Stigma Among Drug Treatment Providers and People who Use Opioids. Substance Abuse: Research and Treatment 16, pages 117822182211038.
Crossref
Crossref
Lila Flavin, Babak Tofighi, Noa Krawczyk, Daniel Schatz, Jennifer McNeely & Jenna Butner. (2022) Low Threshold Telemedicine-based Opioid Treatment for Criminal Justice Involved Adults During the COVID-19 Pandemic: A Case Report. Journal of Addiction Medicine 16:1, pages e59-e61.
Crossref
Crossref
Noa Krawczyk, Adetayo Fawole, Jenny Yang & Babak Tofighi. (2021) Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review. Addiction Science & Clinical Practice 16:1.
Crossref
Crossref
Elizabeth Chiarello. (2021) Pharmacists should treat patients who have opioid use disorders, not police them. Journal of the American Pharmacists Association 61:6, pages e14-e19.
Crossref
Crossref
Courtney D. Nordeck, Megan Buresh, Noa Krawczyk, Michael Fingerhood & Deborah Agus. (2021) Adapting a Low-threshold Buprenorphine Program for Vulnerable Populations During the COVID-19 Pandemic. Journal of Addiction Medicine 15:5, pages 364-369.
Crossref
Crossref
Jan Gryczynski, Joshua D. Lee, Kristi Dusek, Ryan McDonald, Anjalee Sharma, Mia Malone, Laura B. Monico, Anna Cheng, Angela DeVeaugh-Geiss & Howard D. Chilcoat. (2021) Use of non–prescribed buprenorphine in the criminal justice system: Perspectives of individuals recently released from incarceration. Journal of Substance Abuse Treatment 127, pages 108349.
Crossref
Crossref
Hayley D. Germack. (2020) States Should Remove Barriers to Advanced Practice Registered Nurse Prescriptive Authority to Increase Access to Treatment for Opioid Use Disorder. Policy, Politics, & Nursing Practice 22:2, pages 85-92.
Crossref
Crossref
Laura B. Monico, Jan Gryczynski, Joshua D. Lee, Kristi Dusek, Ryan McDonald, Mia Malone, Anjalee Sharma, Anna Cheng, Angela DeVeaugh-Geiss & Howard Chilcoat. (2021) Exploring nonprescribed use of buprenorphine in the criminal justice system through qualitative interviews among individuals recently released from incarceration. Journal of Substance Abuse Treatment 123, pages 108267.
Crossref
Crossref
Lauren Caton, Hannah Cheng, Hélène Chokron Garneau, Tammy Fisher, Briana Harris-Mills, Brian Hurley, Sandra Newman & Mark P. McGovern. (2021) COVID-19 Adaptations in the Care of Patients with Opioid Use Disorder: a Survey of California Primary Care Clinics. Journal of General Internal Medicine 36:4, pages 998-1005.
Crossref
Crossref
Andrea Jakubowski & Aaron Fox. (2021) Letter in Reply. Journal of Addiction Medicine 15:1, pages 88-89.
Crossref
Crossref
Noa Krawczyk, Michael I. Fingerhood & Deborah Agus. (2020) Lessons from COVID 19: Are we finally ready to make opioid treatment accessible?. Journal of Substance Abuse Treatment 117, pages 108074.
Crossref
Crossref
Noa Krawczyk, Ramin Mojtabai, Elizabeth A. Stuart, Michael Fingerhood, Deborah Agus, B. Casey Lyons, Jonathan P. Weiner & Brendan Saloner. (2020) Opioid agonist treatment and fatal overdose risk in a state‐wide US population receiving opioid use disorder services. Addiction 115:9, pages 1683-1694.
Crossref
Crossref
Caitlin A. Madison & Shoshana Eitan. (2020) Buprenorphine: prospective novel therapy for depression and PTSD. Psychological Medicine 50:6, pages 881-893.
Crossref
Crossref
Reuben J. Strayer, Kathryn Hawk, Bryan D. Hayes, Andrew A. Herring, Eric Ketcham, Alexis M. LaPietra, Joshua J. Lynch, Sergey Motov, Zachary Repanshek, Scott G. Weiner & Lewis S. Nelson. (2020) Management of Opioid Use Disorder in the Emergency Department: A White Paper Prepared for the American Academy of Emergency Medicine. The Journal of Emergency Medicine 58:3, pages 522-546.
Crossref
Crossref
Brandon del Pozo, Lawrence S. Krasner & Sarah F. George. (2021) Decriminalization of Diverted Buprenorphine in Burlington, Vermont and Philadelphia: An Intervention to Reduce Opioid Overdose Deaths. Journal of Law, Medicine & Ethics 48:2, pages 373-375.
Crossref
Crossref
Rachel P. Winograd, Claire A. Wood, Erin J. Stringfellow, Ned Presnall, Alex Duello, Phil Horn & Tim Rudder. (2020) Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs. Journal of Substance Abuse Treatment 108, pages 55-64.
Crossref
Crossref
Sharon StancliffDanielle GreeneHoward A. Zucker. (2019) Why 24 State and Territorial Health Officials Support Buprenorphine Deregulation. American Journal of Public Health 109:12, pages 1678-1679.
Crossref
Crossref
Noa Krawczyk, Megan Buresh, Michael S. Gordon, Thomas R. Blue, Michael I. Fingerhood & Deborah Agus. (2019) Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap. Journal of Substance Abuse Treatment 103, pages 1-8.
Crossref
Crossref
Stephanie K. Rubel, Matthew Eisenstat, Jessica Wolff, Michael Calevski & Sasha Mital. (2022) Scope of, Motivations for, And Outcomes of Diverted Buprenorphine Among People Using Buprenorphine: A Scoping Review. SSRN Electronic Journal.
Crossref
Crossref